BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) clinicalTrial	Dec. 31, 2022 USD ($)	Jan. 01, 2022 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Research and development	$ 7,500
Number of Phase1/2 clinical trials in process | clinicalTrial	1
Number of Phase 3 clinical trials in process | clinicalTrial	3
Reduction in additional paid-in capital	$ (1,291,863)	$ (1,059,975)
Reduction in accumulated deficit	$ (1,100,554)	$ (1,014,223)
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Convertible notes payable			$ 44,700
Reduction in additional paid-in capital			74,900
Reduction in accumulated deficit			$ 30,200